Please login to the form below
RNA interference
This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk hits pause on rival to Hemlibra for haemophilia
Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.
Latest news
-
China backs use of Roche’s Actemra for coronavirus
Alnylam meanwhile says it is working with Vir Biotech on RNA interference drugs targeting ‘highly-conserved regions’ of COVID-19 RNA.
-
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease
RNA interference (RNAi) drug lumasiran works upstream of the deficient enzyme, switching off production of a substrate that it converts to oxalate.
-
FDA clears Alnylam’s second RNAi drug for rare disease
Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari.
-
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
It also said shifting the neuroscience projects to the US will make it easier for Lilly apply new technologies like RNA interference and gene therapy to the neuroscience projects.
-
Arbutus hit hard as new hep B drug fails on safety
Last December, the company reported disappointing results in a phase 2 trial of a RNA interference candidate called ARB-1467, handing a competitive advantage to Arrowhead Pharmaceuticals whose rival drug ... It has since abandoned the programme in favour
More from news
Approximately 1 fully matching, plus 42 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
More than a decade of research into its RNA interference (RNAi) drugs generated the first ever approval of a drug in this category towards the end of 2018, and the company
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Silence appoints chief medical officer
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Senior Account Executive
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Publications Director
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Associate Account Director
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Medical Editor
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Account Management
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- GSK’s revenue drops by 18% in Q1 as performance pressures mount
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy
- Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Virtual Trials, Remote Care, & Cross-Border Collaboration: Ethical & Legal Challenges
- Live Webinar: Blockchain in Healthcare: Predictions for the Post-COVID World
- Live Webinar: Digital Health for Improving Care in Disadvantaged Populations
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Illingworth Research Group wins ‘prestigious’ Queen’s Award
- Working in true partnership in a time of change
- Live Webinar: The Future of Digital Pills
- Total COVID-19 vaccine spending to reach $157bn by 2025, says report
- NICE sets out plans for ‘ambitious’ five-year strategy
- Pfizer CEO says oral COVID-19 pill could be ready by the end of the year
- PMEA 2021 has officially launched – with a new online entry system
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
- COVID-proof: How Teams are Creating Launch Intensity thru Adversity
- Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
